What is the difference between Venetoclax/Venetoclax and Garovar?

Venetoclax/Venetoclax (Venetoclax) and Obinutuzumab (Obinutuzumab) are two drugs that play an important role in cancer treatment. They each have unique mechanisms of action, indications and dosage methods. Here's a detailed comparison of the two drugs.

Looking at the basic properties of the drugs, venetoclax and venetoclax are actually different names for the same drug. Venetoclax is the common name marketed in China, while venetoclax is its other common name, with the trade name Weikelai. This drug is also sold overseas under the trade names of Venclexta and Venclyxto. As an oral anti-cancer drug, it mainly helps restore the normal apoptosis (self-death) mechanism by targeting the specific protein Bcl-2, thereby inhibiting the growth of cancer cells. Venetoclax/Venetoclax has shown promise in treating certain types of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and can also be used in combination with other drugs to treat patients 75 years of age or older with newly diagnosed acute myeloid leukemia (AML) or adults with comorbidities that preclude the use of intensive induction chemotherapy.

In contrast, Obinutuzumab (Obinutuzumab) is a completely different drug, and its generic name is obinutuzumab. It is produced by the Swiss pharmaceutical company Roche and is primarily used to treat chronic lymphocytic leukemia (CLL) and follicular lymphoma (FL). Jialuohua is a humanized monoclonal antibody that inhibits the growth and spread of cancer cells by inhibiting specific target antigens. Its mechanism of action is to target the CD20 antigen expressed on the surface of pre-B lymphocytes and mature B lymphocytes. After binding to the CD20 antigen, it mediates B cell lysis and induces the direct death of B cells in lymphoma, thereby clearing lymphoma tumors.

In terms of indications, although both Venetoclax and Garova are used to treat hematological tumors, their specific indications are different. Venetoclax/Venetoclax focuses more on the treatment of CLL, SLL and AML under specific conditions, while Garovar is mainly used for the treatment of CLL and FL. This reflects differences in the mechanisms of action and targets of the two drugs. In terms of treatment strategies, venetoclax and Garovar can be used together to enhance the efficacy.

In terms of medication method, Venetoclax/Venetoclax is an oral anti-cancer drug with the characteristics of convenient medication and good patient compliance. Jialuohua needs to be administered through intravenous infusion, and its dosage and cycle need to be adjusted according to the patient's specific conditions. This requires doctors to closely monitor the patient's response and condition changes during medication to ensure the safety and effectiveness of the medication.

In addition, there are differences in side effects between the two drugs. Common adverse reactions of venetoclax/venetoclax include neutropenia, diarrhea, nausea, anemia, upper respiratory tract infection, thrombocytopenia and fatigue. The side effects of Jialuohua include immune-related adverse reactions, infections, infusion-related reactions, and hematological toxicity. The occurrence of these side effects may be related to factors such as the mechanism of action of the drug, individual differences among patients, and the method of medication.

References:https://www.swagcanceralliance.nhs.uk/wp-content/uploads/2021/11/Obinutuzumab-and-Venetoclax-v1.pdf